News | May 07, 2025
AstraZeneca's enhertu improved pCR in early-stage breast cancer
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
ekincare has raised a total funding of $22M since 2015 till date
Delivers robust earnings performance, successfully navigating a dynamic environment
Bayer expects 2025 to be the most difficult year of its turnaround
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Subscribe To Our Newsletter & Stay Updated
